Azboy I, et al. - Forty-five papers were involved in this systematic review, researchers recognized any variations between high and low dose as well as the duration for aspirin thromboprophylaxis following TJA as outlined by former studies. Between individuals receiving low-dose or high-dose aspirin, no important variations in symptomatic pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), 90-day mortality or major bleeding was discovered. A greater risk of major bleeding was noted in individuals treated with aspirin for < 4 weeks vs patients treated for 4 weeks, which could be associated with premature cessation or differential reporting. A statistically greater 90-day mortality of individuals treated with aspirin for < 4 weeks was observed, in comparison with individuals who were treated for 4 weeks. No important variation between the incidence of PE or DVT and the durations of aspirin treatment could be ruled out. In conclusion, for venous thromboembolism thromboprophylaxis in TJA individuals, the review implies that low dose aspirin is noninferior to high dose aspirin. Moreover, a greater risk of major bleeding and 90-day mortality could be noted in individuals treated with aspirin for less than 4 weeks in comparison with patients treated for a longer-term.